Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | DRD4 | P21917 | 4/20 | 0.54 |
| ▸ | DRD2 | P14416 | 3/20 | 0.54 |
| ▸ | DRD3 | P35462 | 2/20 | 0.54 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29363627 | 0.86 | SIGMAR1 (0.60) | SIGMAR1HTR1ADRD4DRD2DRD3 | |
| SCHEMBL14144244 | 0.85 | SIGMAR1 (0.54) | KDM4ELMNAALOX15SIGMAR1HTR1A | |
| SCHEMBL14601668 | 0.83 | SIGMAR1 (0.60) | SIGMAR1HTR1AKCNA3 | |
| SCHEMBL25124613 | 0.82 | DRD4 (0.54) | KDM4ELMNAALOX15SIGMAR1HTR1A | |
| SCHEMBL7369144 | 0.82 | KDM4E (0.45) | KDM4ELMNAALOX15SIGMAR1HTR1A | |
| SCHEMBL14385616 | 0.82 | DRD4 (0.50) | KDM4ELMNAALOX15SIGMAR1HTR1A | |
| SCHEMBL7910148 | 0.82 | NPSR1 (0.60) | KDM4ELMNAALOX15SIGMAR1DRD2 | |
| SCHEMBL25124915 | 0.82 | SIGMAR1 (0.55) | KDM4ELMNAALOX15SIGMAR1DRD4 | |
| SCHEMBL10241118 | 0.82 | SIGMAR1 (0.57) | SIGMAR1HTR1ADRD2 | |
| SCHEMBL1157579 | 0.82 | SIGMAR1 (0.49) | KDM4ESIGMAR1HTR1ADRD4DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240160464-A1 | INSTRUCTION SENDING METHOD AND APPARATUS | BEIJING BYTEDANCE NETWORK TECHNOLOGY CO., LTD. (CN) | 2024-05-16 | — | — | US | claimed |
| CN-117478625-A | High-performance Unikernel virtual machine communication method and device based on vmfunc | 浙江大学 | 2024-01-30 | — | — | CN | claimed |
| CN-108874500-B | Application program safety protection method based on hardware virtualization technology | 南京大学 | 2022-10-18 | — | — | CN | claimed |
| WO-2022213769-A1 | INSTRUCTION SENDING METHOD AND APPARATUS | 北京字节跳动网络技术有限公司 | 2022-10-13 | — | — | WO | claimed |
| WO-2026100506-A1 | DEVICE, METHOD PERFORMED BY DEVICE FOR WIRELESS POWER TRANSMISSION, AND PROGRAM | キヤノン株式会社 | 2026-05-15 | — | — | WO | disclosed |
| EP-4398138-B1 | VIRTUALIZATION-BASED PLATFORM PROTECTION TECHNOLOGY | INTEL CORP (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4315051-B1 | APPARATUS AND METHOD FOR MANAGING UNSUPPORTED INSTRUCTION SET ARCHITECTURE (ISA) FEATURES IN A VIRTUALIZED ENVIRONMENT | INTEL CORP (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12583882-B2 | Equatorially modified polymer linked multimers of guansine-3′, 5′-cyclic monophosphates | MIRECA MEDICINES GMBH (DE) | 2026-03-24 | — | — | US | disclosed |
| US-12572378-B2 | Secure arbitration mode to build and operate within trust domain extensions | INTEL CORPORATION (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260056855-A1 | COST REDUCED HIGH RELIABILITY FAULT TOLERANT COMPUTER ARCHITECTURE | STRATUS TECHNOLOGIES IRELAND LTD. (IE) | 2026-02-26 | — | — | US | disclosed |
| US-12554657-B2 | Virtualization-based platform protection technology | INTEL CORPORATION (US) | 2026-02-17 | — | — | US | disclosed |
| US-20250390443-A1 | VIRTUALIZATION-BASED PLATFORM PROTECTION TECHNOLOGY | INTEL CORPORATION (US) | 2025-12-25 | — | — | US | disclosed |
| US-20100179140-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100121049-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100121049-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-7652028-B2 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-01-26 | — | — | US | disclosed |
| US-7652028-B2 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-01-26 | — | — | US | disclosed |
| US-20100004220-A1 | Indenoisoquinolinone Analogs and Methods of Use Thereof | INOTEK PHARMACEUTICALS CORPORATION | 2010-01-07 | — | — | US | disclosed |
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260056855-A1 | COST REDUCED HIGH RELIABILITY FAULT TOLERANT COMPUTER ARCHITECTURE | KCNN4, OXSR1, INF2 | KDM4E 3370/4885LMNA 1516/4885ALOX15 4453/4885 |
| US-12554657-B2 | Virtualization-based platform protection technology | HPN, POT1, AVPR2 | KDM4E 2430/4885LMNA 3988/4885ALOX15 4402/4885 |
| US-12583882-B2 | Equatorially modified polymer linked multimers of guansine-3′, 5′-cyclic monophosphates | PDE7A, PRKG1, NT5C3B | KDM4E 1316/4885LMNA 2067/4885ALOX15 4414/4885 |
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | TNNI3, IDH2, GLS | KDM4E 2660/4885LMNA 407/4885ALOX15 262/4885 |
| US-20250390443-A1 | VIRTUALIZATION-BASED PLATFORM PROTECTION TECHNOLOGY | HPN, AVPR2, AVPR1A | KDM4E 2493/4885LMNA 4061/4885ALOX15 3929/4885 |
| US-20100121049-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | TNNI3, IDH2, GLS | KDM4E 2660/4885LMNA 407/4885ALOX15 262/4885 |
| US-12572378-B2 | Secure arbitration mode to build and operate within trust domain extensions | INTS9, TIMM9, MAX | KDM4E 2043/4885LMNA 834/4885ALOX15 4840/4885 |
| US-20100004220-A1 | Indenoisoquinolinone Analogs and Methods of Use Thereof | TNNI3, IDH2, GLS | KDM4E 2660/4885LMNA 407/4885ALOX15 262/4885 |
| US-20100179140-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | TNNI3, IDH2, GLS | KDM4E 2660/4885LMNA 407/4885ALOX15 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.